Skip Therapeutics is developing RNA therapeutics for treatment of rare genetic diseases.

Scientific approach

A proprietary computational engine is used to identify disease-causing mutations. Antisense oligonucleotides (ASO) are then developed to modulate splicing in order to generate functional proteins. This approach allows identification of relevant patient cohorts and design of ASOs.

link to Skip Therapeutics page

Indications

Rare genetic diseases

Team

Prof. Erez Levanon, PhD, Inventor

Prof. Rotem Karni, PhD, Inventor

Ariel Feiglin, PhD, CSO

Scroll to top